Analysis of NIH-CPSI score, clinical efficacy and safety of prostate cancer patients treated with prostaglandin E and alpha blockers
Objective To investigate the effect of the treatment of prostatitis and NIH-CPSI score and clinical therapeutic effect of prostate cancer treated with prostaglandin E and alpha blockers.MethodsThe clinical data of patients with prostatitis treated in The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine from March 2015 to August 2016 in were retrospectively analyzed.The patients were divided into control group and observation group.The control group was treated with the treatment of the first aid, while the observation group was treated with the combination of the first and the second.The therapeutic effects of the two groups were observed and compared between the two groups before and after treatment NIH-CPSI score, prostate fluid routine, cytokine levels and adverse reactions.ResultsIn the observation group, the treatment efficiency was 97.78%, significantly higher than the control group (85%), the difference was statistically significant (χ2=4.575, P=0.032);Two groups of patients before treatment NIH-CPSI score no difference, after treatment, the observation group of pain or discomfort, voiding symptoms, quality of life and total score were lower than the control group(P<0.05);Two groups of patients before treatment, no difference in the prostatic fluid, after treatment, the observation group was higher than the control group, the number of white blood cells was lower than the control group(P<0.05);There was no difference in the levels of cytokines before and after treatment in the two groups.After treatment, the levels of TNF-α, IL-6 in the observation group were lower than those in the control group(P<0.05).There were no obvious adverse reactions such as liver and kidney injury during the treatment of two groups of patients.ConclusionThe treatment of prostatitis combined with alpha blocker has good therapeutic effect, can significantly improve the clinical symptoms, and has good application value.
the forefront of Shu TongprostatitisNIH-CPSIcytokines
NETL
NSTL
万方数据
维普
